Company intelligence / Profile preview

LensGen

Irvine, California, United Stateslensgen.com ↗

Ownership: Private
Development stage: Phase 1

Overview

LensGen has developed Juvene™, a curvature-changing fluid-optic intraocular lens designed to restore youthful vision by mimicking the natural accommodation of the human eye. The company received FDA Investigational Device Exemption approval in late 2021 to begin a pivotal clinical study for cataract and presbyopia patients. Early clinical data from the Grail Study and surgeon experience suggest significant potential for improved visual outcomes across all distances[5].

Therapeutic areas: Ophthalmology
Modalities: DeviceIntraocular lens (IOL)
Industry: Implantable Medical Devices

Drug pipeline

1 asset

Juvene

Phase 1

Indications: Cataracts, Presbyopia

Partnerships

Support from one of the largest medical device companies in the world (name not disclosed)

Beyond the preview

Go deeper on LensGen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LensGen.

Explore the full profile